Indications: Niraparib is prescribed for:

• Continuation therapy for advanced ovarian cancer in patients who have responded to platinum-based chemotherapy.

Pharmacology: Niraparib operates as a PARP inhibitor, obstructing PARP enzymes involved in DNA repair. This impediment prevents cancer cells from mending their DNA, leading to their demise.

Dosage and Administration: The standard dose is 300 mg taken orally once daily. Adjustments may be required for Niraparib Tosylate Monohydrate equivalent to Niraparib 100 mg. It can be ingested with or without food.

Interactions: Niraparib could interact with other drugs, emphasizing the necessity to divulge all medications, encompassing over-the-counter medications, vitamins, and herbal supplements, to healthcare providers.

Side Effects: Common adverse reactions include nausea, vomiting, fatigue, anemia, reduced appetite, diarrhea, and abdominal pain. More severe effects might encompass bone marrow suppression and an increased risk of specific cancers.

Precautions and Warnings: Niraparib may induce bone marrow suppression, prompting periodic blood tests to monitor blood cell counts. Patients should also be monitored for indications of new cancers.

Overdose Effects: If an overdose occurs, supportive measures are essential. There isn’t a specific antidote, and treatment concentrates on managing symptoms.